Search results
UPDATE 1-Johnson & Johnson to acquire Proteologix for $850 million
Reuters via Yahoo Finance· 4 hours agoJohnson & Johnson said on Thursday it would acquire Proteologix for $850 million in cash, as it looks to gain access to the privately held company's experimental atopic < ...
Coexistence of psoriatic arthritis, atopic dermatitis may offer treatment insights
Medical Xpress· 2 days agoPsoriatic arthritis (PsA) and atopic dermatitis (AD) can coexist, and the presence of both...
J&J to buy Proteologix and its dual-targeting antibody drugs for $850M
BioPharma Dive via Yahoo Finance· 5 hours agoThe deal is part of a plan by J&J to build a portfolio of “differentiated” bispecific antibodies, an...
Mount Sinai Awarded $6.6 Million From National Ins | Newswise
Newswise· 11 hours agoNew York, NY – The Icahn School of Medicine at Mount Sinai Health System is spearheading a collaborative effort to investigate dupilumab as a treatment for children with alopecia ...
East Bay biotech raises $105 million, aims to enter clinical trials with eczema drug - San Francisco...
The Business Journals· 6 days agoAttovia Therapeutics said the funding was led by Goldman Sachs Alternatives and included...
The Best Body Washes for Eczema to Gently Cleanse Inflamed Skin
US Weekly· 3 days agoTo learn why certain body washes work better than others for eczema, it’s helpful to understand the...
J&J hooks Proteologix for $850M cash, reeling in a roster of early bispecifics
FierceBiotech· 2 hours agoJohnson & Johnson is shelling out $850 million to buy Proteologix, getting hold of a young roster of...
Dupixent set for FDA review in adolescent chronic inflammatory sinus disease
Pharmaceutical Technology via Yahoo Finance· 3 days agoMany patients also have other type 2 inflammatory diseases such as asthma. Dupixent was first...
13 Penny Stocks with Insider Buying in 2024
Insider Monkey via Yahoo Finance· 4 days agoIn this article, we will take a detailed look at the 13 Penny Stocks with Insider Buying in 2024. If you want to skip our detailed analysis and see the...
Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with...
Benzinga· 3 days agoFood and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for Dupixent® (dupilumab) as an add-on maintenance treatment ...